Clinical Trial Detail

NCT ID NCT03683433
Title Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Azacitidine + Enasidenib

Age Groups: adult senior

Additional content available in CKB BOOST